HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Settling Prop 65 Suits Is Easier, Cheaper Than Fighting, Firms Say

This article was originally published in The Rose Sheet

Executive Summary

It can be easier to settle suits filed under California's Proposition 65 than to fight them, even in cases where firms say they are not in violation

You may also be interested in...



Cosmetics Firms To Phase Out Cocamide DEA Under Prop 65 Settlements

At a time when California regulators are considering amendments to Proposition 65 to stem a rising tide of related lawsuits, 14 personal-care manufacturers and retailers have settled suits filed by the Center for Environmental Health for violating the regulation and failing to properly warn consumers about the use of cocamide DEA in products.

NGO’s Prop 65 Lawsuit Targets Undisclosed Cocamide DEA

Oakland, Calif.-based Center for Environmental Health calls out more than 100 manufacturers and retailers of cocamide deithanolamine-containing products that it says are noncompliant with the state’s Proposition 65 regulation. CEH has filed suit against four of them.

Prop 65 Litigators Turning Sights On Beauty Industry, Lawyer Says

Prop 65 suits tend to hit industries in waves, and there are indications that the beauty industry is next, says Angela Diesch, attorney for Sacrament, Calif.-based Greenberg Traurig. Marketers of products containing methyl eugenol, lead or cocamide DEA should ensure they are complying with the California law.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015666

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel